Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis

Palisade Bio, Inc. (Nasdaq: PALI) has received clearance from Health Canada for its Clinical Trial Application for the ASCENTRA-UC trial, which evaluates PALI-2108 in patients with moderately to severely active ulcerative colitis. This approval allows the company to expand its clinical trial activities in Canada, complementing prior regulatory clearance in the United States. The primary efficacy results from the 12-week induction period of the study are anticipated in the second half of 2027.